Catalog Products » PGF, His, Mouse
Manual
Manual
COAs

PGF, His, Mouse

Placental growth factor (PGF) is another member of the VEGF family of cytokines with pro-angiogenic and pro-inflammatory effects. Retinal inhibition of PGF in combination with VEGF-A prevents vascular leakage and CNV possibly via modulating their own expression in mononuclear phagocytes. PGF-related, optimized strategies to target inflammation-mediated angiogenesis may help to increase efficacy and reduce non-responders in the treatment of wet AMD patients.
$340.00
Z06306-100

Ask us a question
Product Introduction
Species Mouse
Protein Construction
PGF (Val19-Pro158)_x000D_
Accession # P49764		 His
N-term C-term
Purity > 95% as determined by Bis-Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 16.99 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 30-40 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.
Back

PGF, His, Mouse

Immobilized PGF, His, Mouse, His Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for Human VEGF R1, hFc Tag with the EC50 of 54.3ng/ml determined by ELISA. »

PGF, His, Mouse

PGF, His, Mouse on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »

<
>

Background
Target Background Placental growth factor (PGF) is another member of the VEGF family of cytokines with pro-angiogenic and pro-inflammatory effects. Retinal inhibition of PGF in combination with VEGF-A prevents vascular leakage and CNV possibly via modulating their own expression in mononuclear phagocytes. PGF-related, optimized strategies to target inflammation-mediated angiogenesis may help to increase efficacy and reduce non-responders in the treatment of wet AMD patients.
Synonyms PlGF; PGF; PGFL; SHGC-10760; D12S1900; PlGF-2
Back

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.